Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Lexaria Bioscience (LEXX) over the last 15 years, with Q4 2025 value amounting to -$5099.0.

  • Lexaria Bioscience's Cash from Investing Activities rose 8651.2% to -$5099.0 in Q4 2025 from the same period last year, while for Nov 2025 it was -$210314.0, marking a year-over-year decrease of 1283.97%. This contributed to the annual value of -$243019.0 for FY2025, which is 2885.08% down from last year.
  • As of Q4 2025, Lexaria Bioscience's Cash from Investing Activities stood at -$5099.0, which was up 8651.2% from -$157878.0 recorded in Q3 2025.
  • Over the past 5 years, Lexaria Bioscience's Cash from Investing Activities peaked at $270384.0 during Q1 2021, and registered a low of -$157878.0 during Q3 2025.
  • Over the past 5 years, Lexaria Bioscience's median Cash from Investing Activities value was -$36323.0 (recorded in 2022), while the average stood at -$29365.9.
  • In the last 5 years, Lexaria Bioscience's Cash from Investing Activities skyrocketed by 2703850000.0% in 2021 and then tumbled by 250215000.0% in 2022.
  • Lexaria Bioscience's Cash from Investing Activities (Quarter) stood at -$58215.0 in 2021, then soared by 40.15% to -$34842.0 in 2022, then fell by 14.88% to -$40026.0 in 2023, then rose by 5.55% to -$37804.0 in 2024, then soared by 86.51% to -$5099.0 in 2025.
  • Its Cash from Investing Activities was -$5099.0 in Q4 2025, compared to -$157878.0 in Q3 2025 and -$19443.0 in Q2 2025.